Association between Colistin Dose and Development of Nephrotoxicity

Critical Care Medicine

Volumn 43, Issue 6, 2015, Pages 1187-1193

  Lee, Yu Ji ^a,b   Wi, Yu Mi ^a   Kwon, Yun Jae ^a   Kim, Sung Rok ^a   Chang, Se Ho ^c   Cho, Seong ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Gyeongsang National University   (South Korea)

^c Gyeongsang National University School of Medicine   (South Korea)

Author keywords

colistin; dosing; nephrotoxicity; risk factors

Indexed keywords

ALBUMIN; COLISTIMETHATE; CREATININE; EPIDERMAL GROWTH FACTOR RECEPTOR; GLYCOPEPTIDE; HYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; COLISTIN; SERUM ALBUMIN;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; BODY WEIGHT; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAM NEGATIVE INFECTION; HEMATOCRIT; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEPHROTOXICITY; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ACUTE KIDNEY FAILURE; AGE; AGED; ANTIBIOTIC RESISTANCE; BLOOD; CHEMICALLY INDUCED; DOSE RESPONSE; GRAM-NEGATIVE BACTERIAL INFECTIONS; TIME; VERY ELDERLY;

ACUTE KIDNEY INJURY; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COLISTIN; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; FEMALE; GLOMERULAR FILTRATION RATE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HEMATOCRIT; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SERUM ALBUMIN; TIME FACTORS;

EID: 84937541090     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000000931     Document Type: Article

References (31)

1. Reina R, Estenssoro E, Sáenz G, et al: Safety and effcacy of colistin in Acinetobacter and Pseudomonas infections: A prospective cohort study. Intensive Care Med 2005; 31:1058-1065
2. Kang CI, Song JH: Antimicrobial resistance in Asia: Current epidemiology and clinical implications. Infect Chemother 2013; 45:22-31
3. Sarkar S, DeSantis ER, Kuper J: Resurgence of colistin use. Am J Health Syst Pharm 2007; 64:2462-2466
4. Michalopoulos AS, Tsiodras S, Rellos K, et al: Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: The renaissance of an old antibiotic. Clin Microbiol Infect 2005; 11:115-121
5. Spapen H, Jacobs R, Van Gorp V, et al: Renal and neurological side effects of colistin in critically ill patients. Ann Intensive Care 2011; 1:14
6. Koomanachai P, Tiengrim S, Kiratisin P, et al: Effcacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand. Int J Infect Dis 2007; 11:402-406
7. Martis N, Leroy S, Blanc V: Colistin in multi-drug resistant Pseudomonas aeruginosa blood-stream infections: A narrative review for the clinician. J Infect 2014; 69:1-12
8. Falagas ME, Rafailidis PI, Kasiakou SK, et al: Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin-meropenem combination therapy for multidrug-resistant Gram-negative bacterial infections. Clin Microbiol Infect 2006; 12:1227-1230
9. Levin AS, Barone AA, Penço J, et al: Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999; 28:1008-1011
10. Kallel H, Hergaf L, Bahloul M, et al: Safety and effcacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: A matched case-control study. Intensive Care Med 2007; 33:1162-1167
11. Huang J, Tang YQ, Sun JY: Intravenous colistin sulfate: A rarely used form of polymyxin E for the treatment of severe multidrug-resistant Gram-negative bacterial infections. Scand J Infect Dis 2010; 42:260-265
12. Falagas ME, Fragoulis KN, Kasiakou SK, et al: Nephrotoxicity of intravenous colistin: A prospective evaluation. Int J Antimicrob Agents 2005; 26:504-507
13. Kwon JA, Lee JE, Huh W, et al: Predictors of acute kidney injury associated with intravenous colistin treatment. Int J Antimicrob Agents 2010; 35:473-477
14. Falagas ME, Rafailidis PI, Ioannidou E, et al: Colistin therapy for micro-biologically documented multidrug-resistant Gram-negative bacterial infections: A retrospective cohort study of 258 patients. Int J Antimicrob Agents 2010; 35:194-199
15. Lim LM, Ly N, Anderson D, et al: Resurgence of colistin: A review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy 2010; 30:1279-1291
16. Pogue JM, Lee J, Marchaim D, et al: Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis 2011; 53:879-884
17. Wr M, Jackson GG: Gram-Negative bacteremia I. Etiology and ecology. Arch Intern Med 1962; 110:847-855
18. Ozkan G, Ulusoy S, Orem A, et al: How does colistin-induced nephropathy develop and can it be treated? Antimicrob Agents Chemother 2013; 57:3463-3469
19. Yousef JM, Chen G, Hill PA, et al: Ascorbic acid protects against the nephrotoxicity and apoptosis caused by colistin and affects its pharmacokinetics. J Antimicrob Chemother 2012; 67:452-459
20. Yousef JM, Chen G, Hill PA, et al: Melatonin attenuates colistin-induced nephrotoxicity in rats. Antimicrob Agents Chemother 2011; 55:4044-4049
21. Ozyilmaz E, Ebinc FA, Derici U, et al: Could nephrotoxicity due to colistin be ameliorated with the use of N-acetylcysteine? Intensive Care Med 2011; 37:141-146
22. Kim J, Lee KH, Yoo S, et al: Clinical characteristics and risk factors of colistin-induced nephrotoxicity. Int J Antimicrob Agents 2009; 34:434-438
23. Gauthier TP, Wolowich WR, Reddy A, et al: Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patients. Antimicrob Agents Chemother 2012; 56:2392-2396
24. Rocco M, Montini L, Alessandri E, et al: Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: A retrospective cohort study. Crit Care 2013; 17:R174
25. Rattanaumpawan P, Ungprasert P, Thamlikitkul V: Risk factors for colistin-associated nephrotoxicity. J Infect 2011; 62:187-190
26. Deryke CA, Crawford AJ, Uddin N, et al: Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Agents Chemother 2010; 54:4503-4505
27. Turkoglu M, Dizbay M, Ciftçi A, et al: Colistin therapy in critically ill patients with chronic renal failure and its effect on development of renal dysfunction. Int J Antimicrob Agents 2012; 39:142-145
28. Vicari G, Bauer SR, Neuner EA, et al: Association between colistin dose and microbiologic outcomes in patients with multidrug-resistant gram-negative bacteremia. Clin Infect Dis 2013; 56: 398-404
29. Sun X, Iles M, Weissman C: Physiologic variables and fuid resuscitation in the postoperative intensive care unit patient. Crit Care Med 1993; 21:555-561
30. Ronco C, Kaushik M, Valle R, et al: Diagnosis and management of fuid overload in heart failure and cardio-renal syndrome: The "5B" approach. Semin Nephrol 2012; 32:129-141
31. Payen D, de Pont AC, Sakr Y, et al; Sepsis Occurrence in Acutely Ill Patients (SOAP) Investigators: A positive fuid balance is associated with a worse outcome in patients with acute renal failure. Crit Care 2008; 12:R74